Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-LNC1004 in FAP-Positive Solid Tumors
NCT05723640Phase 1Completed
- Sponsor
- Yantai Lannacheng Biotechnology Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of lutetium Lu 177 LNC1004 in solid tumor (4 arms), sponsored by Yantai Lannacheng Biotechnology Co., Ltd. Primary endpoints: Safety of 177Lu-LNC1004 Injection up to 2 years, Dose-Limiting Toxicities and 1 more. Started Oct 2023; status: completed.
02
Drugs
lutetium Lu 177 LNC1004
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05723640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723640.